Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: A phase III trial of the AGO OVAR, COGI, GINECO, and GEICO-the MIMOSA study

Journal of Clinical Oncology

Volumn 31, Issue 12, 2013, Pages 1554-1561

  Sabbatini, Paul ^a   Harter, Philipp ^b   Scambia, Giovanni ^f   Sehouli, Jalid ^d   Meier, Werner ^e   Wimberger, Pauline ^c   Baumann, Klaus H ^f   Kurzeder, Christian ^f   Schmalfeldt, Barbara ^f   Cibula, David ^f   Bidzinski, Mariusz ^f   Casado, Antonio ^f   Martoni, Andrea ^f   Colombo, Nicoletta ^f   Holloway, Robert W ^f   Selvaggi, Luigi ^f   Li, Andrew ^f   Campo, Jose Del ^f   Karel Cwiertka, ^f   Tamas Pinter, ^f   Jan B Vermorken, ^f   Eric Pujade Lauraine, ^f   Simona Scartoni, ^f   Monica Bertolotti, ^f   Cecilia Simonelli, ^f   Angela Capriati, ^f   Carlo Alberto Maggi, ^f   Jonathan S Berek, ^f   Jacobus Pfisterer, ^f   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b KLINIKEN ESSEN MITTE   (Germany)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e EVANGELISCHES KRANKENHAUS   (Germany)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABAGOVOMAB; ANTIIDIOTYPIC ANTIBODY; CA 125 ANTIGEN; PLACEBO;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CANCER STAGING; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DOUBLE BLIND PROCEDURE; FATIGUE; FEMALE; HUMAN; IMMUNE RESPONSE; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OVARY CARCINOMA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VOLUME;

ADENOCARCINOMA, MUCINOUS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYSTADENOCARCINOMA, SEROUS; DOUBLE-BLIND METHOD; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; SURVIVAL RATE;

EID: 84876529191     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.46.4057     Document Type: Article

References (30)

1. Markman M, Markman J, Webster K, et al: Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: Implications for patient management and clinical trial design. J Clin Oncol 22:3120-3125, 2004 (Pubitemid 41103725)
2. Hall GD, Brown JM, Coleman RE, et al: Maintenance treatment with interferon for advanced ovarian cancer: Results of the Northern and Yorkshire Gynaecology Group randomised phase III study. Br J Cancer 91:621-626, 2004 (Pubitemid 39141614)
3. Alberts DS, Hannigan EV, Liu PY, et al: Randomized trial of adjuvant intraperitoneal alphainterferon in stage III ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy: An Intergroup study. Gynecol Oncol 100:133-138, 2006 (Pubitemid 41815062)
4. Schilder RJ, Brady MF, Spriggs D, et al: Pilot evaluation of high-dose carboplatin and paclitaxel followed by high-dose melphalan supported by peripheral blood stem cells in previously untreated advanced ovarian cancer: A Gynecologic Oncology Group study. Gynecol Oncol 88:3-8, 2003 (Pubitemid 36062658)
5. Lambert HE, Rustin GJ, Gregory WM, et al: A randomized trial comparing single-agent carboplatin with carboplatin followed by radiotherapy for advanced ovarian cancer: A North Thames Ovary Group study. J Clin Oncol 11:440-448, 1993 (Pubitemid 23071039)
6. Sorbe B: Consolidation treatment of advanced ovarian carcinoma with radiotherapy after induction chemotherapy. Int J Gynecol Cancer 13: 192-195, 2003 (suppl 2) (Pubitemid 38228764)
7. Varia MA, Stehman FB, Bundy BN, et al: Gynecologic Oncology Group: Intraperitoneal radioactive phosphorus (32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: A randomized trial of the Gynecologic Oncology Group. J Clin Oncol 21:2849-2855, 2003 (Pubitemid 46621832)
8. Nicoletto MO, Tumolo S, Falci C, et al: A randomized study of epithelial ovarian cancer: Is chemotherapy useful after complete remission? Int J Med Sci 1:116-125, 2004
9. De Placido S, Scambia G, Di Vagno G, et al: Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. J Clin Oncol 22:2635-2642, 2004 (Pubitemid 41103751)
10. Verheijen RH, Massuger LF, Benigno BB, et al: Phase III trial of intraperitoneal therapy with yttrium-90 -labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. J Clin Oncol 24:571-578, 2006 (Pubitemid 46655592)
11. Berek J, Taylor P, McGuire W, et al: Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. J Clin Oncol 27:418-425, 2009
12. Markman M, Liu PY, Wilczynski S, et al: Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 21:2460-2465, 2003 (Pubitemid 46606325)
13. Levine D, Park K, Juretzka M, et al: A phase II evaluation of goserelin and bicalutamide in patients with ovarian cancer in second or higher complete clinical disease remission. Cancer 110:2448-2456, 2007 (Pubitemid 350174930)
14. Berek JS, Taylor PT, Nicodemus CF: CA125 velocity at relapse is a highly significant predictor of survival post relapse: Results of a 5-year follow-up survey to a randomized placebo-controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer. J Immunother 31:207-214, 2008
15. Duffy MJ, Bonfrer JM, Kulpa J, et al: CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use. Int J Gynecol Cancer 15:679-691, 2005 (Pubitemid 41783071)
16. Sabbatini P, Dupont J, Aghajanian C, et al: Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clin Cancer Res 12:5503-5510, 2006 (Pubitemid 44497267)
17. Bafna S, Kaur S, Batra SK: Membrane-bound mucins: The mechanistic basis for alterations in the growth and survival of cancer cells. Oncogene 29: 2893-2904, 2010
18. Gubbels JA, Belisle J, Onda M, et al: Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors Mol Cancer 5:50, 2006
19. Bhattacharya-Chatterjee M, Chatterjee SK, Foon KA: Anti-idiotype antibody vaccine therapy for cancer. Expert Opin Biol Ther 2:869-881, 2002 (Pubitemid 36033253)
20. Leffers N, Fehrmann RS, Gooden MJ, et al: Identification of genes and pathways associated with cytotoxic T lymphocyte infiltration of serous ovarian cancer. Br J Cancer 103:685-692, 2010
21. O'Brien TJ, Beard JB, Underwood LJ, et al: The CA 125 gene: An extracellular superstructure dominated by repeat sequences. Tumour Biol 22: 348-366, 2001 (Pubitemid 34062947)
22. Yin BW, Lloyd KO: Molecular cloning of the ca125 ovarian cancer antigen: Identification as a new mucin, muc 16. J Biol Chem 276:27371-27375, 2001
23. Reinartz S, Wagner U, Giffels P, et al: Immunological properties of a single-chain fragment of the anti-idiotypic antibody ACA125. Cancer Immunol Immunother 49:186-192, 2000 (Pubitemid 30484825)
24. Pfisterer J, du Bois A, Sehouli J, et al: The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer: A phase I trial of the AGO-OVAR. Ann Oncol 17:1568-1577, 2006 (Pubitemid 44548850)
25. Reinartz S, Kǒhler S, Schlebusch H, et al: Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: Immunological response and survival (phase Ib/II). Clin Cancer Res 10:1580-1587, 2004 (Pubitemid 38435546)
26. Berek JS, Taylor PT, Gordon A, et al: Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. J Clin Oncol 22:3507- 3516, 2004 (Pubitemid 41103657)
27. Chekmasova AA, Brentjens RJ: Adoptive T cell immunotherapy strategies for the treatment of patients with ovarian cancer. Discov Med 9:62-70, 2010
28. Anderson KS, Wong J, Vitonis A, et al: p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer. Cancer Epidemiol Biomarkers Prev 19:859-868, 2010
29. Sato E, Olson SH, Ahn J, et al: Intraepithelial CD8- tumor-infiltrating lymphocytes and a high CD8-/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 102:18538-18543, 2005 (Pubitemid 43011261)
30. Walter S, Weinschenk T, Stenzl A, et al: Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med [epub ahead of print on July 29, 2012]